Researchers studying 88 adults with Down syndrome and 43 controls estimated that serum β-synuclein increased approximately two decades before expected Alzheimer’s symptoms, preceding changes in other blood biomarkers. Higher levels correlated with poorer memory and brain changes, but the cross-sectional study could not distinguish whether the earliest increase reflected Alzheimer’s-related synaptic dysfunction, trisomy 21-related neurobiology, or both.